CAYSTON

This brand name is authorized in Austria, Canada, Croatia, Cyprus, Estonia, France, Ireland, Israel, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug CAYSTON contains one active pharmaceutical ingredient (API):

1	Aztreonam UNII XNM7LT65NP - AZTREONAM LYSINE
	Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis.
	Read more about Aztreonam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAYSTON Powder and solvent for nebuliser solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DF01	Aztreonam	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DF Monobactams
Discover more medicines within J01DF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02329840
EE	Ravimiamet	1436172
ES	Centro de información online de medicamentos de la AEMPS	09543002
FR	Base de données publique des médicaments	61054849
GB	Medicines & Healthcare Products Regulatory Agency	174633, 174637
IE	Health Products Regulatory Authority	88132
IL	מִשְׂרַד הַבְּרִיאוּת	7382
LT	Valstybinė vaistų kontrolės tarnyba	1050738, 1056311
NL	Z-Index G-Standaard, PRK	97292
PL	Rejestru Produktów Leczniczych	100308901